



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: August 25, 2008

To: Primary Clinical Research Associates

From: Alex Adjei, M.D.

Re: N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Dear Colleagues,

This notice is to let you know that N0626 (A phase II study of Alimta vs Alimta + Sorafenib) for 2nd line NSCLC has re-opened for accrual. The study was closed as planned in the original study, for interim toxicity analysis, since there were no phase I data of the combination of ALimta+Sorafenib. After reviewing the toxicities, the study has been re-opened, but squamous histology has been excluded.

Please contact me if you have any questions.